1. Scrip
  2. >>Business
  3. >>Deals

Novartis Dives Into Inflammasome Pool With IFM Tre Purchase

 
• By Kevin Grogan

The Swiss major has bought a US biotech that specializes in targeting the NLRP3 pathway in a deal valued at up to $1.58bn.

Splash
Novartis hopes to make a splash in NLRP3 • Source: Shutterstock

Novartis AG is the latest big pharma player to enter one of the hottest areas of anti-inflammatory drug development –NLRP3 inhibition – by spending $310m upfront to acquire IFM Tre, which was only formed last summer.

Boston, MA-headquartered IFM Tre is developing anti-inflammatories that target the NLRP3 (nucleotide-binding domain, leucine-rich repeat-containing receptor pyrin domain containing 3)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By Vibha Ravi

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By Kevin Grogan

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By Manas Mishra

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Private Equity Targets Bavarian Nordic But Major Investor Balks

 
• By Manas Mishra

After “intense negotiations”, Bavarian Nordic’s board plans to recommend a DKK19bn ($2.98bn) offer by private equity firms Nordic Capital and Permira to take the company private.

More from Business

BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327

 
• By Jessica Merrill

The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”

Bayer Stokes Optimism With Guidance Update But Risks Remain

 
• By Aakash Babu

Even though the company’s pharmaceutical business continues to do well, navigating some key stress points will be crucial for Bayer.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: EU tariff deal leaves questions for pharma; Prasad’s CBER exit could bode well for genetic medicines; Winrevair grows but Merck & Co. plans cost cuts; Novo Nordisk selects new CEO; and a look at obesity past the GLP-1s.